[Shingrix photo]
KEY POINTS
- Non-live, recombinant subunit vaccine
- First non-live zoster vaccine to market
- FDA-approved in October 2017 for:
- Prevention of shingles (herpes zoster) in people aged 50 years or older
- In October 2017 the CDC’s Advisory Committee on Immunization Practices (ACIP) voted that…
- Shingrix is recommended for healthy adults aged 50 years and older to prevent shingles and related complications
- Shingrix is recommended for adults who previously received the current shingles vaccine (Zostavax) to prevent shingles and related complications
- Shingrix is the preferred vaccine for preventing shingles and related complications
- Not indicated for prevention of chickenpox
- Efficacy exceeded 90% in phase-III trials which got it FDA-approved
- Given in two intramuscular doses
- Common side effects: muscle pain, headache, shivering, fever, upset stomach, tiredness, injection site pain, injection site redness, or injection site swelling
- Favorable data exists for:
- Adults older than 70 years
- Immunocompromised persons
- Prolonged immunogenicity and safety
- Reportedly CDC has recommended Shingrix over Zostavax for adults over 50 (including in persons already given Zostavax), however an official statement from CDC has yet to be released as of 26 October 2017
- Cost data is pending
RESOURCES
- Shingrix Package Insert
- Shingrix FDA Approval Letter
- CDC Shingles (Herpes Zoster) Webpage
- CDC Shingles/Herpes Zoster Vaccine Recommendations
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. [NEJM 2016]
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults [NEJM 2015]
- A critical appraisal of ‘Shingrix‘, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. [HVI 2017]
- The herpes zoster subunit vaccine. [EOBT 2016]
- Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. [Vaccine 2016]
